Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | APP | P05067 | 11/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163616 | 0.93 | RAD51 (0.55) | RAD51MAPTAPPMEN1KMT2A | |
| SCHEMBL2164542 | 0.87 | MAPT (0.55) | RAD51MAPTAPPMEN1KMT2A | |
| SCHEMBL2163077 | 0.82 | RAD51 (0.60) | RAD51MAPTAPPMEN1KMT2A | |
| SCHEMBL2164507 | 0.82 | APP (0.51) | RAD51MAPTAPP | |
| SCHEMBL2162673 | 0.81 | RAD51 (0.46) | RAD51MAPTAPPMEN1RAB9A | |
| SCHEMBL2162641 | 0.78 | RAD51 (0.51) | RAD51MAPTRAB9A | |
| SCHEMBL20816306 | 0.78 | RAD51 (1.00) | RAD51MAPTAPP | |
| SCHEMBL2163569 | 0.76 | RAD51 (0.43) | RAD51MAPTMEN1RAB9AKMT2A | |
| SCHEMBL12403830 | 0.76 | MAPT (0.45) | RAD51MAPTAPPMEN1RAB9A | |
| SCHEMBL2163050 | 0.76 | RAD51 (0.57) | RAD51APPMEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| WO-2011119565-A1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | RAD51 1902/4885MAPT 1/4885APP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.